$1700 | SAVE $300 | Single User
$3400 | SAVE $600 | Site License
$5100 | SAVE $900 | Enterprise License

Colitis - Pipeline Review, H2 2020

Colitis - Pipeline Review, H2 2020
[Lowest Price Guaranteed: $1,700]

Published by Global Markets Direct: 31 Jul 2020 | 267652 | In Stock
Related Topics: Gas , Healthcare

Introduction

Colitis - Pipeline Review, H2 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H2 2020, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.

Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 1 and 25 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Colitis - Pipeline Review, H2 2020

  • Table of Contents

    Introduction

    Colitis - Overview

    Colitis - Therapeutics Development

    Colitis - Therapeutics Assessment

    Colitis - Companies Involved in Therapeutics Development

    Colitis - Drug Profiles

    Colitis - Dormant Projects

    Colitis - Discontinued Products

    Colitis - Product Development Milestones

    Appendix

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

267652 | GMDHC12372IDB

Number of Pages

116

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Crohn's & Colitis Foundation of America - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryCrohn's & Colitis Foundation of America (CCFA) is a healthcare foundation which offers treatm...
25 Nov 2016 by Global Data USD $213 (normally
USD $251)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Ulcerative Colitis Global Clinical Trials Review, H2, 2016
Ulcerative Colitis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report,...
28 Sep 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Crohn's & Colitis Foundation of America - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryCrohn's & Colitis Foundation of America (CCFA) is a healthcare foundation that offers treatme...
27 Apr 2016 by Global Data USD $213 (normally
USD $251)
More Info
SAVE 15% today! Colitis Global Clinical Trials Review, H1, 2016
Colitis Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “Colitis G...
11 Mar 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Crohn's & Colitis Foundation of America - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryCrohn's & Colitis Foundation of America (CCFA) is a healthcare foundation that offers treatme...
09 Mar 2016 by Global Data USD $213 (normally
USD $251)
More Info
SAVE 15% today! Ulcerative Colitis: Update Bulletin [Feb 2016]
IntroductionGain new KOL insights on the latest events happening in Ulcerative Colitis. Topics cover...
01 Feb 2016 by FirstWord Pharma USD $846 (normally
USD $995)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
Introductionipeline drugs are poised to reshape the way doctors treat ulcerative colitis (UC). But w...
01 Dec 2015 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
IntroductionThe Ulcerative Colitis (UC) treatment market is already undergoing radical change as new...
03 Dec 2014 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Colitis - Pipeline Review, H2 2020 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...